All In Biotech

Drug Trial Radar · NCT06822790

Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia

A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia (SHASTA-10 Study)

Last checked: Nov 19, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

710

Actual

Start

Apr 9, 2025

Primary completion

Jul 2028

Study completion Jul 2028

Sponsor

Lead sponsor
Arrowhead PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Feb 12, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label study to be conducted in adults with hypertriglyceridemia (HTG) and severe hypertriglyceridemia (SHTG). Each participant must have completed all required visits per protocol in the parent study AROAPOC3-2003 (USA and Canada participants only; NCT# 05413135), AROAPOC3-3001(Canada and Japan participants only; NCT05089084), AROAPOC3-3003 (NCT06347003), AROAPOC3-3004 (NCT06347016) or AROAPOC3-3009 (Argentina, Italy, South Africa, and Spain; NCT06347133). Subjects who previously met all eligibility requirements for AROAPOC3-3003 or AROAPOC3-3004 and were not permitted to proceed to randomization per the Sponsor's direction in order to prevent excessive over-enrollment may also be enrolled in this trial. The subjects must meet all other applicable eligibility criteria prior to enrollment and have an HbA1c results of \<=10% within 30 days prior to Day 1. Subjects entering this OLE from AROAPOC3-2003 must meet the following additional criteria to be considered for enrollment in addition to applicable eligibility criteria: 1. HbA1c ≤10% within 30 days prior to Day 1 2. Completed AROAPOC3-2001 prior to entry into AROAPOC3-2003 AND fulfill either (c) or (d) 3. Baseline fasting TG level of ≥500 mg/dL and prior history of acute pancreatitis at the time of enrollment into AROAPOC3-2001 4. Baseline fasting TG level of ≥1000 mg/dL at the time of enrollment into AROAPOC3-2001 All eligible participants will receive plozasiran administered subcutaneously (SC) approximately every 3 months for 24 months. Participants will be counseled to remain on the specified low-fat diet throughout the study in accordance with local standard of care.

Conditions

  • Hypertriglyceridemia

Interventions

  • Plozasiran InjectionDrug

    ARO-APOC3 injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Treatment-Emergent Adverse Events (TEAEs)Time frame: From first dose of study drug through Month 24

Locations

253 sites in 24 countries. Site status is shown where the registry gives one.

  • Research Site 21

    Bakersfield, California

  • Research Site 9

    Beverly Hills, California

  • Research Site 11

    Canoga Park, California

  • Research Site 40

    Garden Grove, California

  • Research Site 235

    Huntington Beach, California

  • Research Site 236

    Lake Forest, California

  • Research Site 39

    Lincoln, California

  • Research Site 34

    Oxnard, California

  • Research Site 229

    Palm Springs, California

  • Research Site 275

    Redding, California

  • Research Site 14

    Hialeah, Florida

  • Research Site 154

    Miami, Florida

  • Research Site 1

    Miami Lakes, Florida

  • Research Site 42

    Mt. Dora, Florida

  • Research Site 41

    Orlando, Florida

  • Research Site 16

    Tamarac, Florida

  • Research Site 18

    Tampa, Florida

  • Research Site 237

    Lawrenceville, Georgia

  • Research Site 17

    Park Ridge, Illinois

  • Research Site 43

    Elkhart, Indiana

  • Research Site 157

    Indianapolis, Indiana

  • Research Site 28

    Overland Park, Kansas

  • Research Site 23

    Topeka, Kansas

  • Research Site 12

    Annapolis, Maryland

  • Research Site 44

    Baltimore, Maryland

  • Research Site 30

    Flint, Michigan

  • Research Site 290

    Minneapolis, Minnesota

  • Research Site 33

    Jackson, Mississippi

  • Research Site 32

    Olive Branch, Mississippi

  • Research Site 2

    Jefferson City, Missouri

  • Research Site 232

    St Louis, Missouri

  • Research Site 29

    Fremont, Nebraska

  • Research Site 3

    Omaha, Nebraska

  • Research Site 77

    Summit, New Jersey

  • Research Site 72

    Long Island City, New York

  • Research Site 233

    New York, New York

  • Research Site 228

    New York, New York

  • Research Site 273

    Riverhead, New York

  • Research Site 37

    Asheboro, North Carolina

  • Research Site 36

    Morehead City, North Carolina

Showing 40 of 253 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.